Providing Appropriate Risk Information on Genome Editing for Patients

Trends Biotechnol. 2016 Feb;34(2):86-90. doi: 10.1016/j.tibtech.2015.12.002.


Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off-target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.

Keywords: CRISPR/Cas9; clinical application; genome editing; informed consent; off-target mutation; society.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clustered Regularly Interspaced Short Palindromic Repeats*
  • Gene Targeting / methods*
  • Genetic Therapy / adverse effects*
  • Genetic Therapy / methods*
  • Genome, Human*
  • Humans
  • Mutation*
  • Patient Acceptance of Health Care
  • Risk*